Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Protein Test Improves Survival Prediction for Oropharyngeal Carcinoma

By LabMedica International staff writers
Posted on 13 Feb 2014
A simple protein test could prove more useful in predicting survival chances for patients with head-and-neck cancer compared to existing methods.

There is an increasing incidence of human papillomavirus (HPV)-positive oropharyngeal squamous cell cancers (OPSCC) mostly associated with favorable outcomes and a tumor suppressor protein could be a surrogate marker for HPV positivity in OPSCC. More...


Scientists at the University of Manchester (UK) collected formalin-fixed, paraffin-embedded blocks from hospitals where 217 patients were being treated for OPSCC. One approach for detecting HPV-associated oral cancer relies on finding HPV DNA in the tumor sample, but these DNA-based tests may not accurately classify the tumor. Another approach is to use a marker of HPV rather than testing for HPV DNA directly. The p16 protein usually disappears in tumors that are not caused by HPV infection and has been proposed as a surrogate marker of HPV.

Blocks with confirmed tumor presence were selected for immunohistochemistry (IHC), which was carried out using the CINtec histology kit (MTM Laboratories, Heidelberg, Germany). Stained slides were scanned using the Leica SCN 400 (Wetzlar, Germany). The cyclin-dependent kinase inhibitor protein p16 expression was scored as positive if there was a strong and diffuse brown staining of the nucleus and cytoplasm in equal to or greater than 70% of the tumor specimen. Of the 92% of the OPSCC originating from tonsil and tongue base sites, 61% were p16 positive. The study showed that p16 is the single most important prognostic variable in OPSCC, surpassing traditional prognostic factors for both cancer-specific survival (CSS) and recurrence-free survival (RFS). Furthermore, disease stage has no prognostic significance in p16-positive patients, highlighting the need for routine p16 assessment in OPSCC.

Catharine M.L. West, PhD, the lead author of the study said, “Despite presenting with a more advanced stage of cancer, patients whose tumors tested positive for p16 had greater survival when compared with p16-negative patients. Applying this test in the clinic could help guide treatment decisions and potentially allow doctors to choose more appropriate and tailored treatments. Many studies have now shown p16 status is strongly linked to survival. Now we have shown the test works better than routine staging for some cancers, we would recommend this test be offered as standard.” The study was published in the November 2013 issue of the journal Clinical Oncology.

Related Links:

University of Manchester
MTM Laboratories
Leica



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.